In Myelodysplastic syndrome, hypomethylating agents, 5-azacytidine and 5-aza-2′-deoxycytidine (decitabine), which work by inhibiting DNA methyltransferase, have been approved (MDS). Cytopenias, nausea, pain, and local reactions in injection sites are the most common side effects of hypomethylating agents. Toxicity associated with other organ functions is extremely uncommon. As the fourth...